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Cytotoxic drugs are a mainstay of cancer treatment, 
but response rates are notoriously variable between 
patients. While some of this disparity is explained by 
host genetics, it is becoming increasingly clear that other 
factors are involved. A recent report from our laboratory 
[1] suggests that the plethora of microorganisms that 
inhabit our bodies, or microbiome, are important 
contributors to the efficacy of fluoropyrimidine-based 
drugs.
The mammalian microbiome is extraordinarily 
complex, consisting of a hundred trillion cells and 
thousands of species that collectively encode 5 million 
distinct genes. Although the idea that gut microbes can 
affect drug responses has existed for at least half a century, 
the complexity and technical limitations have made 
mechanistic insights difficult. Microbes may interfere with 
host-targeted drugs directly (metabolic transformation) 
and/or indirectly (regulating host metabolism and/or 
cellular signalling). For example, gut bacteria are capable 
of metabolically reactivating the chemotherapeutic 
CPT-11, increasing toxicity, and unexpected microbial 
hydrolysis of the antiviral sorivudine resulted in the 
death of patients undergoing fluoropyrimidine-based 
chemotherapy (reviewed in [2]).
Host-microbe-drug interactions are commonly 
studied in mice through the use of antibiotics or in a 
germ-free environment. Despite such studies having made 
important contributions to our understanding of host-
microbe interactions, they are expensive, low-throughput 
and remain complex, making the underlying biological 
mechanisms difficult to unravel. The nematode C. 
elegans offers a simplified and tractable, yet evolutionary 
conserved, host-microbe model which addresses many of 
these drawbacks. Like us, worms establish a symbiotic 
relationship with their microbes, requiring them for 
optimal development and metabolic health [3].
We utilised the unique advantages of the C. elegans 
model to explore how bacteria can change the host 
response to the antimetabolite pro-drug 5-fluorouracil 
(5-FU), commonly used in the treatment of colorectal 
cancer (CRC) [3]. 5-FU is intracellularly converted into 
cytotoxic fluoropyrimidines by ribonucleotide pathways, 
the predominant of which (FdUMP) inhibits a key 
enzyme, thymidylate synthase (TS), thereby blocking the 
production of thymidylate and disrupting DNA replication 
and cellular division [4]. Given the evolutionary 
conservation of these pathways in prokaryotes, we 
postulated that microbes may be capable of modifying the 
host’s response to this class of drugs.
Fluoropyrimidines inhibit development, fecundity 
and cancer-like germline hyper-proliferation in C. 
elegans, enabling a robust and high-throughput readout 
of drug efficacy. We observed up to 80-fold changes in 
drug toxicity depending on the bacterial strain the animal 
was colonized with. To thoroughly define the microbial 
mechanism(s) behind modulation of drug efficacy on 
the host, we devised an innovative 3-way host-microbe-
drug high-throughput screen of C. elegans using the 
Keio collection of E. coli single deletion mutants [1, 5]. 
From more than 55,000 individual conditions tested, this 
screen identified vitamins B6 and B9 and ribonucleotide 
metabolism as key contributors to 5-FU action in the host. 
Disruption of the bacterial B6 and B9-associated pathways 
(glycine cleavage system and one-carbon metabolism), 
which are linked to ribonucleotide metabolism via TS, 
reduced drug efficacy in the host. These results suggested 
bacterial ribonucleotide metabolism as the primary 
mediator of drug toxicity in C. elegans [1].
To mechanistically explore the bacterial mediation 
of 5-FU toxicity on the host, we performed in vivo and in 
vitro measurements together with metabolomic analysis 
and found that microbes have the capacity to modify and 
excrete activated toxic fluoronucleotides including FUMP, 
FUTP and FdUMP, which are ultimately responsible for 
the increased efficacy of drug therapy. These activated 
compounds, as well as the toxic effects of 5-FU, were 
abrogated in a genetically modified bacterial strain lacking 
genes encoding the enzymes of ribonucleotide salvage: 
upp, udk, and udp. Crucially, profiles of 5-FU metabolites 
isolated from worms were identical to profiles of the 
bacterial strain they were co-cultured with, indicating 
that bacterial metabolism dictates drug metabolism rather 
than that of the worm. In addition, we demonstrated that 
the ability for bacteria to convert 5-FU leads to reduced 
germline hyperproliferation and promotes survival in 
nematode cancer models [1]. 
We also identified a secondary mechanism by 
which bacteria are able to manipulate fluoropyrimidine 
efficacy in C. elegans. We found bacteria deficient in the 
enzyme nucleoside diphosphate kinase (ndk) increased 
drug toxicity on the host via a mechanism independent of 
the accumulation of modified fluoronucleotides. Rather, 
metabolomic profiling revealed that disruption of bacterial 
ndk results in deoxynucleotide imbalance, which sensitises 
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the host to 5-FU-induced DNA damage through amplified 
autophagy. Similarly, the gut microbe Fusobacterium 
nucleatum promotes resistance to combinatorial 
chemotherapy of 5-FU and Oxaliplatin in CRC patients 
by modulating autophagy [6]. Altogether, these studies 
demonstrate that microbes regulate chemotherapy by 
direct biochemical conversion of toxic chemotherapy 
pro-drugs [1, 5] or indirectly by regulating the tumour 
microenvironment [1, 6].
The power of understanding the mechanisms behind 
microbial manipulation of chemotherapy and other drugs 
is difficult to exaggerate. The ability to tweak a living 
system and “pull the strings” by a variety of interventions 
holds great potential as an avenue for personalised 
medicine. Routine profiling of patient microbiome 
composition, host and microbiome genetics and disease 
status, could lead to predictive models to ensure optimal 
treatment outcomes. Therapeutics could be designed to 
directly target the microbiota, or patients colonised with 
‘designer microbes’, to ensure optimal drug activity. 
It is almost certain that the currently reported host-
microbe-drug interactions are only the tip of the iceberg, 
and that there are many exciting times ahead in our 
continued comprehension of how bugs modulate drugs.
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